

Guanfacine Hydrochloride Market

Market Report | 2025-05-01 | 257 pages | Datastring Consulting

AVAILABLE LICENSES:

- Multi User License \$1399.00

Report description:

Description

The market, for Guanfacine hydrochloride was estimated at \$498.1 million in 2024; and it is anticipated to increase to \$812.6 million by 2030 with projections indicating a growth to around \$1.2 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 8.5% over the forecast period.

Segmentation

To see report segmentation please view the table of contents, or ask us for samples.

Table of Contents:

Chapter 1: Executive Summary - Major Markets & Their Performance - Statistical Snapshots

Chapter 2: Research Methodology

2.1: Axioms & Postulates

2.2: Market Introduction & Research Methodology - Estimation & Forecast Parameters / Major Databases & Sources

Chapter 3: Market Dynamics

3.1: Market Overview - Drivers / Restraints / Opportunities / M4 Factors

3.2: Market Trends

3.2.1: Introduction & Narratives

3.2.2: Market Trends - Impact Analysis (Short, Medium & Long Term Impacts)

3.3: Supply Chain Analysis

3.4: Porter's Five Forces - Suppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry

Chapter 4: Global Guanfacine Hydrochloride Market Size, Opportunities & Strategic Insights, by Prescription Type

4.1: Extended-Release

4.2: Immediate-Release

Chapter 5: Global Guanfacine Hydrochloride Market Size, Opportunities & Strategic Insights, by Application Areas

5.1: ADHD

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2: Hypertension
- 5.3: Anxiety Disorders
- 5.4: Sleep Disorders
- 5.5: Other CNS Disorders
- Chapter 6: Global Guanfacine Hydrochloride Market Size, Opportunities & Strategic Insights, by Patient Demographics
 - 6.1: 6-17 years
 - 6.2: 18 Years & Above
- Chapter 7: Global Guanfacine Hydrochloride Market Size, Opportunities & Strategic Insights, by Therapy Type
 - 7.1: Monotherapy
 - 7.2: Combination Therapy
- Chapter 8: Global Guanfacine Hydrochloride Market Size, Opportunities & Strategic Insights, by Distribution Channel
 - 8.1: Retail Pharmacies
 - 8.2: Hospital Pharmacies
 - 8.3: Online Pharmacies
 - 8.4: Specialty Pharmacies
- Chapter 9: Guanfacine Hydrochloride Market, by Region
 - 9.1: North America Guanfacine Hydrochloride Market Size, Opportunities, Key Trends & Strategic Insights
 - 9.1.1: U.S.
 - 9.1.2: Canada
 - 9.2: Europe Guanfacine Hydrochloride Market Size, Opportunities, Key Trends & Strategic Insights
 - 9.2.1: Germany
 - 9.2.2: France
 - 9.2.3: UK
 - 9.2.4: Italy
 - 9.2.5: The Netherlands
 - 9.2.6: Rest of EU
 - 9.3: Asia Pacific Guanfacine Hydrochloride Market Size, Opportunities, Key Trends & Strategic Insights
 - 9.3.1: China
 - 9.3.2: Japan
 - 9.3.3: South Korea
 - 9.3.4: India
 - 9.3.5: Australia
 - 9.3.6: Thailand
 - 9.3.7: Rest of APAC
 - 9.4: Middle East & Africa Guanfacine Hydrochloride Market Size, Opportunities, Key Trends & Strategic Insights
 - 9.4.1: Saudi Arabia
 - 9.4.2: United Arab Emirates
 - 9.4.3: South Africa
 - 9.4.4: Rest of MEA
 - 9.5: Latin America Guanfacine Hydrochloride Market Size, Opportunities, Key Trends & Strategic Insights
 - 9.5.1: Brazil
 - 9.5.2: Mexico
 - 9.5.3: Rest of LA
 - 9.6: CIS Guanfacine Hydrochloride Market Size, Opportunities, Key Trends & Strategic Insights
 - 9.6.1: Russia
 - 9.6.2: Rest of CIS
- Chapter 10: Competitive Landscape

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.1: Competitive Dashboard & Market Share Analysis
- 10.2: Company Profiles (Overview, Financials, Developments, SWOT)
 - 10.2.1: Amneal Pharmaceuticals LLC
 - 10.2.2: Par Pharmaceutical Companies Inc
 - 10.2.3: Teva Pharmaceuticals USA Inc
 - 10.2.4: Northstar Rx LLC
 - 10.2.5: Mylan Pharmaceuticals Inc
 - 10.2.6: Aurobindo Pharma Ltd
 - 10.2.7: Wockhardt Ltd
 - 10.2.8: Lupin Pharmaceuticals Inc
 - 10.2.9: Mallinckrodt Inc
 - 10.2.10: UDL Laboratories Inc
 - 10.2.11: Actavis Pharma Inc
 - 10.2.12: Sun Pharmaceutical Industries Ltd.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Guanfacine Hydrochloride Market

Market Report | 2025-05-01 | 257 pages | Datastring Consulting

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Multi User License	\$1399.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-08"/>
		Signature	<div style="border: 1px solid black; height: 60px; width: 100%;"></div>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com